Dimerix (ASX:DXB) EBIT per Share: A$-0.07 (TTM As of Dec. 2025)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.21
! 3 Warning Signs
View Full Analysis

What is Dimerix EBIT per Share?

Dimerix ASX:DXB -2.38% 32 EBIT per Share is A$-0.07 as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,181 Biotechnology companies, Dimerix ranks worse than 84673.92% on this metric.

Dimerix's EBIT per Share for the six months ended in Dec. 2025 was A$-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.07.

During the past 5 years, the average EBIT per Share Growth Rate was -6.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was -9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Dimerix's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Dimerix was 69.40% per year. The lowest was -51.60% per year. And the median was 7.20% per year.

ASX:DXB's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Dimerix's EBIT for the six months ended in Dec. 2025 was A$-21.73 Mil.

Dimerix  (ASX:DXB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Dimerix EBIT per Share Related Terms

Dimerix EBIT per Share Historical Data

* Premium members only.

The historical data trend for Dimerix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimerix EBIT per Share Chart

Dimerix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.06 -0.07 -0.06 -0.06

Dimerix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.04 -0.02 -0.03 -0.04
ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Dimerix's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-32.009/560.425
=-0.06

Dimerix's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-21.732/600.256
=-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of A$-0.07 mean?
Dimerix (ASX:DXB) has a EBIT per Share of A$-0.07 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Dimerix and its competitors. According to the industry distribution chart, Dimerix ranks #999999 out of 1181 companies in the Biotechnology industry.
Is Dimerix's EBIT per Share too high?
Dimerix's current EBIT per Share is A$-0.07. Based on the distribution chart, Dimerix ranks #999999 out of 1181 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #999999 out of 1181 companies for EBIT per Share. This places Dimerix in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Dimerix and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimerix's current EBIT per Share is A$-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current EBIT per Share of A$-0.07. The current EBIT per Share is A$-0.07. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current EBIT per Share is A$-0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.21
Price